Clinical Toxicity
| Complaint | Grade 1/2 | Grade 3 |
| Fatigue | 27 (87%) | 1 (3%) |
| Pain | 9 (29%) | 0 (0%) |
| Nausea vomiting | 21 (68%) | 0 (0%) |
| Xerostomia | 1 (3%) | 0 (0%) |
| Anorexia | 7 (23%) | 0 (0%) |
| Stomach complaints | 4 (13%) | 0 (0%) |
| Abdominal discomfort | 3 (10%) | 0 (0%) |
| Diarrhea | 5 (16%) | 0 (0%) |
| Flushing | 1 (3%) | 0 (0%) |
| Other | 22 (71%) | 1 (3%)* |
| Injection site | 1 (3%) | 0 (0%) |
↵* One patient experienced a carcinoid crisis shortly after his first treatment cycle. The carcinoid crisis was treated adequately with continuous infusion of short-acting octreotide, with no residual side effects.